GLP-1 drug for brain bleeding in specific locations
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether a GLP-1 receptor agonist (a diabetes/weight-loss medication) can help reduce brain damage and improve recovery after a specific type of spontaneous brain bleed. The medication may reduce inflammation and protect brain tissue in the early hours after bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Brain bleed (hemorrhage) in the putamen or thalamus with specific size limits: 10–30 mL for putamen, 5–15 mL for thalamus, or 5–30 mL if both areas affected
- Moderate-to-severe stroke symptoms: NIHSS score between 6 and 25, and Glasgow Coma Scale score of at least 10
- Symptoms started within 24 hours before hospital arrival
- Good health before the stroke: able to walk independently or with minimal assistance
- Not a candidate for emergency brain surgery at the time of enrollment
- No blood clotting disorder, anticoagulant use, or other secondary causes of bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a non-invasive ultrasound device to help clear blood clots from the brain after a spontaneous bleed. It may be an option for people with small to medium-sized bleeds who do not need surgery.
This study tests whether the drug tranexamic acid can help stop bleeding in the brain when given early. It is for people with a spontaneous brain bleed who are awake and can be treated within 6 hours.
This study looks at how inflammation and changes in the blood-brain barrier occur after a spontaneous brain bleed. Researchers use special brain imaging and scans to understand these processes, which may help improve treatment in the future.
This trial tests a minimally invasive surgery to remove blood clots deep in the brain caused by spontaneous bleeding. It aims to improve recovery for patients who meet specific criteria, such as clot size and time since symptoms started.
This study tests a medicine (a GLP-1 receptor agonist) given along with the standard clot-removal procedure for people who have had a severe stroke from a large blockage. The goal is to see if the medicine helps improve recovery by protecting the brain.
This study tests if adding a GLP-1 receptor agonist (a type of diabetes medicine that also helps blood vessels) to standard clot removal can improve recovery after a severe stroke. It is for people who had a clot removal for a large artery blockage and can start the drug within 6 hours.
Hear when a new Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.